SkIN hydrAtion Evaluation With TeRAhertz Scanning (SINATRA)
Cancer, Skin Cancer, Dry Skin; Eczema
About this trial
This is an interventional diagnostic trial for Cancer focused on measuring medical device
Eligibility Criteria
Inclusion Criteria
- Aged 18 years and over
- Diagnosed with dry skin conditions (e.g. eczema, psoriasis, scars etc.)
- Capacity to give informed consent
- Confirmed or suspected skin cancer (incompletely excised BCC with histologically proven radial margin involvement, biopsy proven BCC or pigmented lesions suspicious of malignant melanoma) .
- Diagnosed with an incompletely excised basal cell carcinoma skin cancer (either radial margin involvement on primary excision or following diagnostic punch biopsy).
- Clinically suspicious pigmented skin lesion (suspected melanoma) with a plan for surgical biopsy
- Capacity to give informed consent
Exclusion Criteria:
- Study Arm 1 ( benign dry skin condition) • Previous allergy or sensitivity to propriety emollients in common usage (e.g. E45®, Aveeno®, Doublebase®etc.).
Sites / Locations
- University Hospital Coventry and Warwickshire NHS Trust
Arms of the Study
Arm 1
Arm 2
Other
Other
Dry skin condition
Skin cancer
2. The second arm will consist of 50 patients with benign dry skin conditions (eczema, psoriasis, skin grafts, scars etc.) and will compare the water content of their skin before and after application of a propriety emollients in common usage (e.g. E45®, Aveeno®, Doublebase®). This will add to the existing dataset that has been recorded from healthy non-patient volunteers (unpublished data, University of Warwick). This may help to guide patient-specific emollient selection in the future.
1. One arm will consist of 100 patients with known or suspected skin cancer (skin cancer defined as: incompletely excised BCC with histologically proven radial margin involvement; biopsy proven BCC, or pigmented lesions suspicious of malignant melanoma). Images will be taken in the clinic prior to planned skin surgery and later compared to the formal histology results after the primary (melanoma) or residual (BCC) tumour has been removed.